Venmax Drugs and Pharmaceuticals Limited (BOM:531015)

BOM:531015 Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	3.45	-0.11	0.65	2.26	18.46	-1.62
Depreciation & Amortization	0.05	0.06	0.07	0.08	0.09	0.1
Asset Writedown & Restructuring Costs	0.19	0.19	-	-	-	-
Other Operating Activities	-0.04	-0.04	-0.01	0	0	0.01
Change in Accounts Receivable	-31.46	-9.53	0.36	-	-0	0.02
Change in Inventory	-15.29	-0.58	-	-	-	2.16
Change in Accounts Payable	14.39	5.25	-2.25	-1.42	0.06	0.63
Change in Other Net Operating Assets	-34.45	-18.17	1.2	-0.95	0.44	1.35
Operating Cash Flow	-63.16	-22.9	0.02	-0.03	19.05	2.64
Operating Cash Flow Growth	-	-	-	-	621.97%	-
Short-Term Debt Issued	-	-	-	0.03	-	-
Total Debt Issued	30.57	-	-	0.03	-	-
Short-Term Debt Repaid	-	-3.03	-	-	-19.8	-1.9
Total Debt Repaid	-3.03	-3.03	-	-	-19.8	-1.9
Net Debt Issued (Repaid)	27.55	-3.03	-	0.03	-19.8	-1.9
Other Financing Activities	91.76	50.73	-	-	-	-
Financing Cash Flow	119.31	47.7	-	0.03	-19.8	-1.9
Miscellaneous Cash Flow Adjustments	-	-	-	-	-0	-
Net Cash Flow	56.15	24.8	0.02	-	-0.75	0.74
Free Cash Flow	-63.16	-22.9	0.02	-0.03	19.05	2.64
Free Cash Flow Growth	-	-	-	-	621.97%	-
Free Cash Flow Margin	-206.37%	-283.69%	-	-	-	157.18%
Free Cash Flow Per Share	-12.16	-4.37	0.00	-0.01	3.64	0.50
Cash Income Tax Paid	0.21	-	0.23	-	-	-
Levered Free Cash Flow	-70.77	-29.5	-1.32	-3.5	-0.27	3.25
Unlevered Free Cash Flow	-70.77	-29.5	-1.32	-3.5	-0.27	3.25
Change in Working Capital	-66.82	-23.01	-0.69	-2.37	0.5	4.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.